NPS' Australian Prescriber has provided a brief summary of the role of newly approved Ilevro (nepafenac), by Novartis, for prevention and treatment of pain and inflammation associated with cataract surgery.
After administration, nepafenac penetrates the cornea and is rapidly metabolised to amfenac by hydrolases, the article explains.
Nepafenac and amfenac work by potently inhibiting cyclo-oxygenase (COX) 1 and 2 enzymes.
Dosing is one drop per day for 15 days starting the day prior to surgery - go to nps.org.au for more.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Oct 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Oct 17
